10-Q: Zymeworks Reports Strong Q3 Revenue Growth, Advances Pipeline

Zymeworks Inc. reported a significant increase in Q3 2025 revenue driven by collaboration milestones and royalties, while advancing its wholly-owned oncology and AIID pipeline programs.

Summary

• Net loss for Q3 2025 improved to $19.6 million from $29.85 million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved to $39.9 million from $99.189 million in the same period of 2024.
• Revenue from research and development collaborations increased by 73% to $27.6 million in Q3 2025 compared to $16.0 million in Q3 2024.
• Nine-month revenue increased by 128% to $103.5 million in 2025 from $45.3 million in 2024.
• Key milestone payments received include $25.0 million from J&J for pasritamig entering Phase 3, $14.0 million from GSK for a clinical milestone, $7.5 million from BMS for a commercial license option exercise, and $20.0 million from BeOne for zanidatamab BLA approval in China.
• Cash, cash equivalents, and marketable securities totaled $299.4 million as of September 30, 2025, providing liquidity for at least the next twelve months.
• The company voluntarily discontinued the clinical development of ZW171 in September 2025.
• Preparations for the Phase 1 study of ZW220 have been paused to accelerate ZW251 development.
• Zanidatamab received conditional marketing authorization from the European Commission in July 2025 and conditional approval from China's NMPA in May 2025 for HER2+ BTC.
• Initial clinical data for ZW191 were presented in October 2025, with dose optimization in ovarian cancer expected in Q4 2025.
• The IND for ZW251 was cleared by the FDA in July 2025, and the first patient was dosed in October 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and improved net loss, driven by significant collaboration milestones and expanded market access for zanidatamab. Progress in the wholly-owned pipeline is also positive. However, the discontinuation of ZW171 and pausing of ZW220, along with the ongoing need for substantial future funding and inherent risks of clinical development, temper the overall sentiment. The financial position is stable for the short term, but long-term profitability remains uncertain.

Positives

• Significant increase in Q3 2025 revenue to $27.6 million (73% increase year-over-year) and 9-month revenue to $103.5 million (128% increase year-over-year).
• Net loss improved substantially in both Q3 2025 ($19.6 million vs $29.85 million in Q3 2024) and the nine-month period ($39.9 million vs $99.189 million in 9M 2024).
• Received multiple significant milestone payments: $25.0 million from J&J, $14.0 million from GSK, $7.5 million from BMS, and $20.0 million from BeOne.
• Zanidatamab received conditional marketing authorization in Europe and conditional approval in China for HER2+ BTC, expanding its market reach.
• The company maintains a strong liquidity position with $299.4 million in cash resources, sufficient for at least the next twelve months.
• Advancement of wholly-owned pipeline candidates, including initial clinical data for ZW191 and IND clearance and first patient dosing for ZW251.
• The company's evolving business strategy aims to enhance long-term stockholder value through thoughtful capital allocation and a partnership-driven model.

Negatives

• Voluntary discontinuation of the ZW171 clinical development program due to an unfavorable benefit-risk profile.
• Pausing of ZW220 Phase 1 study preparations, indicating a delay in its development.
• Accumulated deficit increased to $886.5 million as of September 30, 2025.
• Interest income decreased due to reduced cash balances and lower average yields on investments.
• The company expects to continue incurring losses for the foreseeable future.
• Conditional approvals for zanidatamab in China and Europe are contingent on confirmatory trials, with a risk of revocation if clinical benefit is not verified.

Risks

• Limited number of product candidates, which are still in preclinical or clinical development, and risk of not obtaining regulatory approval or experiencing significant delays.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes; previous results may not be predictive.
• Product candidates may have undesirable side effects that could delay or prevent marketing approval or limit sales.
• Significant competition from other drugs and therapies, including those from major pharmaceutical companies with greater resources.
• Uncertainty of broad market acceptance for zanidatamab or any future approved product candidates among physicians, patients, and third-party payors.
• Inability to successfully use therapeutic platforms to build a pipeline of product candidates.
• Potential for product liability lawsuits, which could result in substantial liabilities and limit commercialization efforts.
• Security breaches, data loss, and other disruptions could compromise sensitive information and expose the company to liability.
• Current and future legislation (e.g., Inflation Reduction Act, state drug pricing laws) may increase the difficulty and cost of commercialization and affect pricing.
• History of significant losses since inception and anticipation of continued losses, with no guarantee of achieving or sustaining profitability.
• Requirement for substantial additional funding, which may not be available on acceptable terms or at all, potentially leading to delays or cessation of development programs.
• Tax law changes (e.g., OBBB Act, Subpart F income rules) could adversely affect the business and financial condition.
• Dependence on collaborative relationships with Jazz and BeOne for zanidatamab's development and commercialization, with risks of adverse decisions, manufacturing difficulties, or termination of agreements.
• Reliance on third-party manufacturers for product candidate supply and on other third parties for clinical trial monitoring and support.
• Inability to obtain, maintain, and enforce patent and trade secret protection for product candidates and related technology.
• Stock price volatility and potential for the market price to drop below the price paid by stockholders.
• Delaware law and company bylaws might delay, discourage, or prevent a change in control or management changes.
• Risks associated with being a smaller reporting company, including reduced reporting and disclosure requirements.
• Potential failure to maintain an effective system of internal control over financial reporting.
• Additional risks for holders of Exchangeable Shares, including lack of market listing and uncertain tax treatment.
• Uncertainty regarding future share repurchases and their impact on stockholder value.
• Economic, political, regulatory, and other risks associated with international operations, including geopolitical instability, trade barriers, and currency fluctuations.
• Adverse effects from public health outbreaks and pandemics on clinical trials, supply chains, and financial markets.
• Exposure to federal and state anti-kickback, fraud and abuse, false claims, transparency, and health information privacy and security laws.
• Potential for employee misconduct or improper activities.
• Costs and inefficiencies resulting from the 2022 Redomicile Transactions.

Future Outlook

The company anticipates continued losses for the foreseeable future as it increases research and development expenditures for product candidates and clinical/preclinical activities. It expects existing cash resources of $299.4 million to fund operations and capital expenditures for at least the next twelve months. The long-term strategy involves leveraging anticipated royalty and milestone revenues from zanidatamab and existing partnerships to fund continued R&D and grow self-contained royalty income, while also pursuing external programs and opportunistic investments. Top-line progression-free survival (PFS) data from the HERIZON-GEA-01 study of Ziihera are expected in Q4 2025. Dose optimization for ZW191 in ovarian cancer is also planned for Q4 2025. An IND submission for ZW209 is expected in 1H 2026, and a non-U.S. regulatory filing for ZW1528 Phase 1 clinical studies is expected in 2H 2026.

Management Comments

• "We look forward to reporting on the top-line progression-free survival (PFS) data from the HERIZON-GEA-01 study of Ziihera expected in 4Q-2025."
• "Based on the preliminary efficacy data and the tolerable safety profile observed [for ZW191], we intend to initiate dose optimization in ovarian cancer in 4Q-2025 to further evaluate ZW191s clinical activity and safety to help inform our registrational strategy."
• "We are encouraged by published research demonstrating the potential of targeting GPC3 with an antibody in HCC patients... and believe that ADC-based targeting of GPC3 could enable a novel and effective approach to treatment of HCC."
• "We have paused the preparations for the commencement of a Phase 1 study of ZW220 to help facilitate the accelerated development of ZW251. However, we believe ZW220 remains a highly differentiated, IND-ready asset with strong clinical, commercial, and partnership potential."
• "We expect to submit an IND to commence Phase 1 clinical studies for ZW209 in 1H-2026, with equivalent non-U.S. applications to be submitted thereafter."
• "We expect to submit a non-U.S. regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2H-2026, with further non-U.S. applications to be submitted thereafter."
• "We continue to develop and advance additional product candidates in multiple different product formats for selected therapeutic indications in solid tumors, hematological cancers, and AIID, with further potential IND applications in 2027 and beyond."
• "Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part."

Industry Context

Zymeworks operates in the highly competitive biopharmaceutical industry, focusing on next-generation multifunctional biotherapeutics for cancer and autoimmune/inflammatory diseases. The company leverages its proprietary Azymetric, Drug Conjugate, EFECT, and ProTECT platforms to develop differentiated antibody-based therapies. The recent conditional approvals for zanidatamab in China and Europe, following FDA accelerated approval, position it as a key player in the HER2+ BTC market, a niche but significant indication. The industry is characterized by high R&D costs, long development timelines, and intense competition from major pharmaceutical and biotechnology companies. The company's strategy of pursuing a partnership-driven model for later-stage development and commercialization aligns with a common industry approach to mitigate risk and leverage external infrastructure, especially for a clinical-stage company with a diverse but early-stage pipeline. The focus on ADCs and multispecific antibodies reflects current trends in oncology drug development.

Comparison to Industry Standards

• Zanidatamab's FDA accelerated approval, NMPA conditional approval (China), and European Commission conditional marketing authorization for HER2+ BTC position it as a first-in-class dual HER2-targeted bispecific antibody in this indication, setting a new standard of care.
• The discontinuation of ZW171 due to an unfavorable benefit-risk profile after Phase 1 dose escalation is a common occurrence in early-stage drug development, reflecting the high attrition rate in the biopharmaceutical industry.
• The pausing of ZW220 development to accelerate ZW251 demonstrates a strategic reprioritization of pipeline assets, a common practice in biotech to optimize resource allocation towards higher-potential programs.
• The company's reliance on collaboration agreements with major pharmaceutical companies like Jazz, BeOne, J&J, GSK, BMS, Daiichi Sankyo, and Merck for development, commercialization, and non-dilutive funding is a standard industry model for clinical-stage biopharmaceutical companies to de-risk and accelerate programs.
• The potential future milestone payments of up to $1.51 billion for zanidatamab and over $4 billion from other platform partnerships are substantial, indicating strong validation of the company's technology platforms by industry leaders.
• The company's cash runway of at least 12 months, supported by $299.4 million in cash resources, is a reasonable liquidity position for a clinical-stage biotech, though the need for "substantial additional funding" for long-term plans is typical for companies in this sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that would reasonably be expected to have a material adverse effect on its business, financial condition, operating results, or cash flows.
• The company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business from time to time.

Related Party Transactions

• EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. (together EcoR1) net exercised 5,086,521 pre-funded warrants in full on June 26, 2025. EcoR1 is a related party due to its beneficial ownership of the company's outstanding common shares.
• Mr. Gregory Ciongoli, following his appointment as a director, purchased 415,000 shares of common stock for $4,988,000 in a private placement on August 10, 2025.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth, improved net loss, and pipeline advancements, but also dilution risk from future capital raises and stock price volatility. The stock repurchase program aims to return capital to shareholders.
• Employees: Changes in management roles and board composition, including the appointment of an Acting Chief Development Officer, may impact organizational structure and strategic direction. Discontinuation of ZW171 program could affect specific R&D teams.
• Customers/Patients: Continued development and regulatory approvals for zanidatamab in new territories (China, Europe) expand treatment options for HER2+ BTC patients. Advancement of other pipeline candidates (ZW191, ZW251) offers future therapeutic potential.
• Strategic Partners: Strong milestone payments from partners like J&J, GSK, BMS, and BeOne indicate successful collaboration and progress in licensed programs, reinforcing the value of Zymeworks' platforms.
• Creditors: Improved financial performance and a solid cash position for the next 12 months reduce immediate credit risk, but the long-term need for substantial funding remains.

Next Steps

• Report top-line progression-free survival (PFS) data from the HERIZON-GEA-01 study of Ziihera in Q4 2025.
• Initiate dose optimization for ZW191 in ovarian cancer in Q4 2025.
• Present three preclinical poster presentations at the Society for Immunotherapy of Cancer in November 2025.
• Submit an IND to commence Phase 1 clinical studies for ZW209 in 1H 2026.
• Submit a non-U.S. regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2H 2026.
• Continue to develop and advance additional product candidates with potential IND applications in 2027 and beyond.
• Conduct confirmatory trials for zanidatamab in HER2+ BTC to verify clinical benefit for continued conditional approvals in China and Europe.
• Evaluate various financing vehicles, including at-the-market equity offering programs, and other financing transactions for future funding needs.
• Potentially pursue additional reorganizations of subsidiaries following the Redomicile Transactions.

Key Dates

Recommendation

Zymeworks demonstrated strong financial improvements with significant revenue growth and reduced net losses, driven by key collaboration milestones and expanded market access for zanidatamab. The advancement of wholly-owned pipeline assets like ZW191 and ZW251 is promising. However, the discontinuation of ZW171 and the pausing of ZW220 highlight the inherent risks and high attrition rates in drug development. While the company has sufficient liquidity for the next 12 months, it will require substantial additional funding for its long-term plans, which could lead to future dilution. The stock repurchase program offers some support, but overall, the company remains a clinical-stage biotech with significant R&D expenses and uncertain long-term profitability. The current valuation likely reflects both the recent successes and the ongoing risks, suggesting a 'hold' position until further clarity on pipeline progression and sustainable profitability emerges.

Keywords

Biopharmaceutical, Oncology, Autoimmune Diseases, Inflammatory Diseases, Antibody Drug Conjugate, ADC, Multispecific Antibody Therapeutics, MSAT, T Cell Engager, TCE, HER2, Zanidatamab, Ziihera, ZW191, ZW251, ZW220, ZW209, ZW1528, Clinical Trials, Drug Development, SEC Filing, Biotechnology, Pharmaceutical, Milestone Payments, Royalties, Research and Development, Corporate Governance, Risk Management, Financial Reporting